What’s New in DFU ? with Professor Keith Harding

News & Event

What’s New in DFU ? with Professor Keith Harding

Between February 20th and 26th 2018, Urgo Medical partnered with the Diabetic Foot Australia association, which aim is to end avoidable amputations in a generation, for 3 events called “What’s new in DFU” in Brisbane, Melbourne and Sydney.

 

DFA 2018 EVENTS 2 - Copy

 

About 250 high level clinicians-podiatrists, nurse unit managers, and wound consultants had the opportunity to learn about the latest research, evidence-based practice by Professor Keith Harding, the “Godfather of woundcare”, and discover the results of Explorer study presented by Associate Professors Bill McGuiness and Paul Wraight.

 

Explorer is the first clinical trial that has been conducted in neuro-ischaemic diabetic foot ulcer to evaluate the efficacy of UrgoStart2. This study has demonstrated the efficacy of UrgoStart unique TLC-NOSF Healing Matrix and heals 60% more patients 60 days sooner vs standard of care alone1. Explorer study meets the most challenging standard in terms of methodology: a double-blind randomized controlled trial conducted on 240 patients, in 5 European countries and 43 investigation centers2.

 

The Explorer launch generated lots of enthusiasm across the clinicians’ community all along the 3.5 hours of discussions on the new horizons for DFU treatment.

 

References  

1. Edmonds M, Lázaro JL, Piaggesi A, et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. The Lancet Diabetes & Endocrinology. Published online December 20, 2017. 2. D.R. Shanahan. The Explorer Study: the first double-blind RCT to assess the efficacy of TLC-NOSF on DFUs. Journal of Wound Care Vol. 22, Iss. 2, 14 Feb 2013, 78 – 81 DFU=diabetic foot ulcer.

 

 

Last update : May 17, 2018